Related Experiment Video
Updated: Sep 28, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Effect of intrarenal renin-angiotensin-aldosterone system on renal function in patients after cardiac surgery
Peiyuan Niu1,2,3, Xuejing Ren1,2,3, Meihao Wu1,2,3
1Department of Nephrology, Henan Provincial People's Hospital; People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, China.
Abstract:
The aim of the study was to investigate the influence of intrarenal RAS on the decrease of renal function in patients undergoing cardiac surgery with cardiopulmonary bypass. This observational study investigated the activation of intrarenal RAS in 24 patients with AKI after cardiac surgery with cardiopulmonary bypass. The activation of intrarenal RAS was determined by urinary angiotensinogen (uAGT), which was measured at 12 hours before surgery, 0 and12 hours after surgery. The results were compared with those of 21 patients without AKI after cardiac surgery with cardiopulmonary bypass. Clinical and laboratory data were collected. Compared with baseline, all patients with cardiac surgery had activation of intrarenal RAS at 0 and 12 hours after surgery. The activation of intrarenal RAS was found significantly higher at both 0 and 12 hours after surgery in AKI group versus non AKI group (6.18 ± 1.93 ng/mL vs 3.49 ± 1.71 ng/mL, 16.38 ± 7.50 ng/mL vs 6.04 ± 2.59 ng/mL, respectively). There was a positive correlation between the activation of RAS at 0 hour after surgery and the decrease of renal function at 48 hours after surgery (r = 0.654, P = .001). These findings suggest that uAGT might be a suitable biomarker for prediction of the occurrence and severity of AKI after cardiac surgery. Inhibition of intrarenal RAS activation might be one the path of future treatment for this type of disease.
Insights
Increased intrarenal renin-angiotensin system (RAS) activation after cardiac surgery is linked to acute kidney injury (AKI). Urinary angiotensinogen (uAGT) may predict AKI occurrence and severity, suggesting RAS inhibition as a potential treatment.
Area of Science:
- Nephrology
- Cardiology
- Surgical Science
Background:
- Cardiac surgery with cardiopulmonary bypass is associated with acute kidney injury (AKI).
- The role of the intrarenal renin-angiotensin system (RAS) in post-cardiac surgery AKI is not fully understood.
- Intrarenal RAS activation may contribute to the decline in renal function following these procedures.
Purpose of the Study:
- To investigate the influence of intrarenal RAS activation on renal function decrease in patients undergoing cardiac surgery.
- To determine if urinary angiotensinogen (uAGT) can serve as a biomarker for predicting AKI after cardiac surgery.
- To explore the potential of inhibiting intrarenal RAS as a therapeutic strategy.
Main Methods:
- Observational study involving 24 patients with AKI and 21 controls without AKI after cardiac surgery.
- Measurement of urinary angiotensinogen (uAGT) at baseline, and 0 and 12 hours post-surgery.
- Collection of clinical and laboratory data to assess renal function and patient outcomes.
Main Results:
- All patients exhibited intrarenal RAS activation post-surgery.
- Patients who developed AKI showed significantly higher uAGT levels at 0 and 12 hours post-surgery compared to the non-AKI group.
- A positive correlation was observed between RAS activation at 0 hours and the decrease in renal function at 48 hours (r=0.654, P=.001).
Conclusions:
- Intrarenal RAS activation is significantly elevated in patients developing AKI after cardiac surgery.
- Urinary angiotensinogen (uAGT) shows promise as a predictive biomarker for AKI occurrence and severity.
- Targeting intrarenal RAS activation may represent a future therapeutic avenue for preventing or treating post-cardiac surgery AKI.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Diuretics
Hormonal Regulation
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure II: Pathophysiology

